24 KB83 KB23 KB200520252009Fon Tacer, Klementinaštevilka:5letnik:60str. 251-255ISSN:0014-8229COBISSID:26146265URN:URN:NBN:SI:doc-PLSE97YEslSlovensko farmacevtsko društvoFarmacevtski vestnikdebelostdiabetes mellitushormonimetabolizemstradanjeHormon stradanja fibroblastni rastni dejavnik 21 - novo zdravilo za debelost in metabolni sindrom?| Fasting hormone fibroblast growth factor 21 - new therapy for obesity and metabolic syndrome?|Increasing prevalence of metabolic diseases is alarming and highlights the need for more effective and safer therapies. Current recommendations for therapy for metabolic syndrome focus on corrections of the individual components. Fibrates are used to treat hyperlipidemia as a predisposing factorto metabolic syndrome and cardiovascular disease. Fibrates mediate theirtherapeutic effects through the peroxisome proliferator-activated receptor alpha (pPARa). PPARa acts as a transcriptional activator of genes involved in lipolysis and ketone body synthesis. The majority of PPARa effectsare mediated by recently discovered starvation hormone - fibroblast growth factor FGF21. Recent evidence from several animal studies indicates that FGF21 induces numerous beneficial metabolic changes without apparent adverse effects. These results suggest that FGF21 could be a novel and attractive drug candidate for the treatment of cardiovascular disease, obesity, and type 2 diabetesTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaSlovensko farmacevtsko društvo